Pharmacological intervention with urate-lowering agents, such as allopurinol, a conventional purine analogue xanthine oxidase (XO) inhibitor, has been used widely for a long period of time in clinical practice to prevent the development of gout and reduce SUA levels. This evidence concerns the gene XDH and gout.